机器人辅助肾部分切除术的演变:技术改进与结局
基于TRoNeS研究组2010至2016年三中心635例临床局限性肾癌患者的RAPN前瞻性数据,平均肿瘤33mm,72.3%达理想手术结局,3.9%发生Clavien-Dindo>2并发症,肿瘤复杂度与未达理想结局相关。
要点
- RAPN治疗临床局限性肾癌安全有效,多数患者可达理想手术结局。
- 肿瘤复杂度是未达理想手术结局的预测因素。
- 平均随访26mo仅观察到2例局部和2例远处复发。
核心结论
- RAPN是治疗临床局限性肾肿瘤的有效微创替代方案。
研究设计与样本
- TRoNeS研究组前瞻性多中心数据库,纳入2010至2016年三所高容量三级中心635例接受RAPN的临床局限性肾癌患者。
主要发现
- 平均年龄60.7yr,平均术前肿瘤大小33mm。
- PADUA评分低、中、高复杂度分别为202例(31.8%)、235例(37.0%)、198例(31.2%)。
- 447例(70.4%)采用经腹腔途径,平均手术时间156.3min,平均估计失血量171ml。
- 25例(3.9%)发生Clavien-Dindo>2的显著术后并发症。
- 459例(72.3%)达到理想手术结局(margin, ischemia, and complication评分),平均随访26mo仅2例局部和2例远处复发。
关键数值与推荐
- 理想手术结局按margin, ischemia, and complication评分定义,459例(72.3%)达到。
- 术前与术后肌酐值无统计学显著差异(p≤0.823)。
- 多因素logistic回归显示肿瘤复杂度与未达理想手术结局的风险相关。
临床怎么用
- RAPN可用于临床局限性肾癌的微创治疗,尤其适合高容量中心。
- 术前应评估肿瘤复杂度(如PADUA评分)以预判手术结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robot-assisted partial nephrectomy (RAPN) is considered a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. OBJECTIVE: To provide further evidence supporting the effectiveness of RAPN in a contemporary patient population treated at one of three tertiary care centers for robotic surgery and to describe the evolution of RAPN-based technical improvements. DESIGN, SETTING, AND PARTICIPANTS: The Transatlantic Robotic Nephron-sparing Surgery (TRoNeS) study group prospectively collected data from 635 patients subjected to RAPN for clinically localized kidney cancer between 2010 and 2016 at three high-volume tertiary care centers. SURGICAL PROCEDURE: RAPN was performed using methods outlined in the supplementary video using either the da Vinci Si or Xi surgical system (Intuitive Surgical, Sunnyvale, CA, USA). MEASUREMENTS: Clinical data were collected within a prospectively maintained multi-institutional database. Intra- and postoperative data as well as surgical outcomes were assessed. Descriptive statistical analysis was performed and multivariable logistic regression models were fitted to determine the predictors of surgical outcomes. RESULTS AND LIMITATIONS: Mean patient age was 60.7yr and mean preoperative tumor size was 33mm. According to the PADUA score, 202 (31.8%) patients had a low-, 235 (37.0%) had an intermediate-, and 198 (31.2%) had a high-complexity tumor. In the majority of patients, a transperitoneal approach was used (n=447; 70.4%). Mean operative time was 156.3min and mean estimated blood loss was 171ml. Overall, 25 (3.9%) patients experienced a significant (Clavien-Dindo >2) complication after surgery. No statistically significant differences between pre- and postoperative creatinine values were observed (p≤0.823). Finally, optimal surgical outcomes defined according to the margin, ischemia, and complication score were achieved in 459 (72.3%) individuals. At a mean follow-up of 26mo, only two local and two distant recurrences of the disease were observed. Finally, in multivariable logistic regression models, tumor complexity was associated with the risk of not achieving optimal surgical outcomes. CONCLUSIONS: RAPN represents an effective minimally invasive alternative to OPN in the treatment of clinically localized renal tumors. PATIENT SUMMARY: We reported contemporary experience with RAPN for the treatment of kidney cancer. RAPN appears to be a safe and effective procedure, resulting in optimal outcomes in the majority of individuals despite tumor complexity.
引用
- Casale P, Lughezzani G, Buffi N, et al. Evolution of Robot-assisted Partial Nephrectomy: Techniques and Outcomes from the Transatlantic Robotic Nephron-sparing Surgery Study Group. Eur Urol. 2018. PMID: 30527786. doi:10.1016/j.eururo.2018.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。